- Conditions
- Hematopoietic Cell Transplantation Recipient, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Hodgkin Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma
- Interventions
- Allogeneic Bone Marrow Transplantation, Allogeneic Hematopoietic Stem Cell Transplantation, Anti-Thymocyte Globulin, Busulfan, Clofarabine, Gemcitabine Hydrochloride, Mycophenolate Mofetil, Peripheral Blood Stem Cell Transplantation, Pharmacological Study, Rituximab, Tacrolimus
- Procedure · Biological · Drug + 1 more
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 12 Years to 65 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2024
- U.S. locations
- 1
- States / cities
- Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–96
of 1,908
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Multiple Myeloma
- Interventions
- Uproleselan, Placebo, Melphalan
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Stem Cell Transplant Complications, Graft Vs Host Disease, Coping Skills, Quality of Life
- Interventions
- Horizon Program, Usual Care
- Behavioral
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphocytic Leukemia, Myelodysplastic Syndromes
- Interventions
- Fludarabine + Total Marrow Irradiation
- Combination Product
- Lead sponsor
- Naoyuki G. Saito, M.D., Ph.D.
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Graft vs. Host Disease
- Interventions
- Ustekinumab, Placebo, Tacrolimus (TAC), Sirolimus
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Chronic Graft-versus-host-disease
- Interventions
- Itacitinib
- Drug
- Lead sponsor
- SCRI Development Innovations, LLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 5
- States / cities
- Denver, Colorado • Nashville, Tennessee • Austin, Texas + 2 more
- Conditions
- Idiopathic Pulmonary Fibrosis and Progressive Fibrotic Interstitial Lung Disease
- Interventions
- Lung Spheroid Stem Cells 100 million, Lung Spheroid Stem Cells 200 million
- Biological
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Hematologic Malignancies, Hematopoietic Stem Cell Transplant (HSCT)
- Interventions
- PUL-042, Placebo
- Drug
- Lead sponsor
- Pulmotect, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 12
- States / cities
- Duarte, California • Atlanta, Georgia • Baltimore, Maryland + 9 more
- Conditions
- Endometriosis, Stem Cell Transplant, Healthy Volunteers
- Interventions
- Not listed
- Lead sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 79 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2017
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Fanconi Anemia
- Interventions
- JSP191, CliniMACS Prodigy System, Depleted Stem Cell Transplant, Rabbit Anti-Thymoglobulin (rATG), Cyclophosphamide, Fludarabine, Rituximab
- Drug · Device · Biological
- Lead sponsor
- Porteus, Matthew, MD
- Other
- Eligibility
- 2 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Sarcoidosis
- Interventions
- Autologous hematopoietic stem cell transplantation, Allogeneic stem cell transplantation
- Biological
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2015
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Sickle Cell Anemia, Severe Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria (PNH), Pure Red Cell Aplasia
- Interventions
- Campath, Chemo and/or TBI Allo SCT
- Drug
- Lead sponsor
- David Rizzieri, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2009
- U.S. locations
- 2
- States / cities
- Orlando, Florida • Durham, North Carolina
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, Myelodysplastic Syndrome
- Interventions
- Cyclophosphamide, Fludarabine, Fludarabine Phosphate, Granulocyte Colony-Stimulating Factor, Hematopoietic Cell Transplantation, Intensity-Modulated Radiation Therapy, Mycophenolate Mofetil, Tacrolimus
- Drug · Biological · Procedure
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 12 Years to 60 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Leukemia, Myeloid, Acute
- Interventions
- VOR33
- Genetic
- Lead sponsor
- Vor Biopharma
- Industry
- Eligibility
- Not listed
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 10
- States / cities
- La Jolla, California • Miami, Florida • Bethesda, Maryland + 5 more
- Conditions
- Minimal Residual Disease, Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Myeloid Leukemia
- Interventions
- Daratumumab, Donor Lymphocyte Infusion, Laboratory Biomarker Analysis
- Biological · Procedure · Other
- Lead sponsor
- Sumithira Vasu
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Acute Leukemia, Myelodysplastic Syndrome, Myeloproliferative Disorders
- Interventions
- ATG dosing platform when combined with standard tacrolimus and mini methotrexate
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Myeloma
- Interventions
- Thalidomide, Lenalidomide, Questionnaires
- Drug · Behavioral
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- B-Cell Prolymphocytic Leukemia, Hypodiploidy, Loss of Chromosome 17p, Plasma Cell Leukemia, Progression of Multiple Myeloma or Plasma Cell Leukemia, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Non-Hodgkin Lymphoma, Recurrent Childhood Hodgkin Lymphoma, Recurrent Childhood Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Plasma Cell Myeloma, Recurrent Small Lymphocytic Lymphoma, Refractory Childhood Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Non-Hodgkin Lymphoma, Refractory Plasma Cell Myeloma, Refractory Small Lymphocytic Lymphoma, t(14;16), t(4;14), T-Cell Prolymphocytic Leukemia, Waldenstrom Macroglobulinemia
- Interventions
- Allogeneic Bone Marrow Transplantation, Allogeneic Hematopoietic Stem Cell Transplantation, Autologous Hematopoietic Stem Cell Transplantation, Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation, Carmustine, Cyclophosphamide, Cytarabine, Etoposide, Fludarabine Phosphate, Laboratory Biomarker Analysis, Melphalan, Mycophenolate Mofetil, Peripheral Blood Stem Cell Transplantation, Tacrolimus, Total-Body Irradiation
- Procedure · Drug · Other + 1 more
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- Up to 75 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2018
- U.S. locations
- 2
- States / cities
- Seattle, Washington • Milwaukee, Wisconsin
- Conditions
- Lymphoma
- Interventions
- bleomycin sulfate, carmustine, cyclophosphamide, dacarbazine, doxorubicin hydrochloride, etoposide, vinblastine, peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 15 Years to 65 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2005
- U.S. locations
- 47
- States / cities
- Birmingham, Alabama • La Jolla, California • San Francisco, California + 29 more
- Conditions
- Hematologic Malignancy, Caregiver
- Interventions
- PATH-C
- Behavioral
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Leukemia, Myelogenous, Chronic, Leukemia, Lymphoblastic, Acute, Leukemia, Myelogenous, Acute, Myeloproliferative-Myelodysplastic Diseases, Lymphoma, Malignant
- Interventions
- Myeloablative Chemotherapy Regimen for Lymphoid Malignancies or Cord Blood Unit Recipients, Myeloablative Chemotherapy Regimen for Non-Cord Blood Unit Recipients with Myeloid Malignancies, Hematopoietic Progenitor Cell Transplantation (HPCT), CNS radiation treatment for ALL with prior CNS disease patients
- Drug · Other · Radiation
- Lead sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2019
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Neuroblastoma
- Interventions
- filgrastim, carboplatin, cisplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, isotretinoin, melphalan, topotecan hydrochloride, vincristine sulfate, autologous bone marrow transplantation, bone marrow ablation with stem cell support, conventional surgery, peripheral blood stem cell transplantation, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 30 Years
- Enrollment
- 495 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2001
- U.S. locations
- 86
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Downey, California + 76 more
- Conditions
- Multiple Myeloma, Newly Diagnosed Multiple Myeloma (NDMM), Autologous Stem Cell Transplant
- Interventions
- Isatuximab, Lenalidomide, Bortezomib Injection, Dexamethasone
- Drug
- Lead sponsor
- Jacob Laubach, MD
- Other
- Eligibility
- 75 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2029
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Mixed Phenotype Acute Leukemia, Acute Leukemia, Myelodysplastic Syndromes, Chronic Myelogenous Leukemia, Chronic Lymphocytic Leukemia, Lymphoma
- Interventions
- Busulfan, Fludarabine, Total-body irradiation, Cyclophosphamide, Melphalan, PBSC Hematopoietic Stem Cell Transplantation (HSCT), Bone Marrow Hematopoietic Stem Cell Transplantation, Post-transplant Cyclophosphamide, Mesna, Tacrolimus, Mycophenolate Mofetil, Patient-Reported Outcomes
- Drug · Radiation · Procedure + 1 more
- Lead sponsor
- Center for International Blood and Marrow Transplant Research
- Network
- Eligibility
- 1 Year and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 39
- States / cities
- Duarte, California • San Francisco, California • Stanford, California + 28 more